SCLX Stock: Scilex Holding Company Stock Price, Analysis & Insights
Get live sclx stock price $23.22, comprehensive Scilex Holding Company stock analysis, charts, news, and expert forecast. Real-time sclx stock data and investment insights.
Loading chart...
Company Overview
Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid management products for the treatment of acute and chronic pain. Its commercial product is ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase III clinical trial to treat lumbosacral radicular pain; SP-103, which is in Phase II clinical trail for the treatment of low back pain; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation that has completed Phase I clinical trial for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.
Company Information
- CEO
- Henry H. Ji
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Employees
- 115
Contact Information
- Address
- 960 San Antonio Road
- Country
- US
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
✓ Higher growth potential with elevated volatility (Beta: 4.62)
Business Model & Strategy
Scilex Holding Company operates in the Drug Manufacturers - General industry, focusing on medical services, pharmaceutical development, and healthcare delivery. Under the leadership of CEO Henry H. Ji, the company navigates Healthcare sector dynamics while pursuing growth opportunities. The Drug Manufacturers - General model requires regulatory compliance, research investment, and patient outcomes to maintain competitiveness and drive shareholder value.
Market Position & Competitive Landscape
Scilex Holding Company competes in the Drug Manufacturers - General within the broader Healthcare. With 175.7 million in market capitalization, the company is positioned as a emerging competitor in its sector. The Healthcare is characterized by demographic shifts, regulatory changes, and medical breakthroughs. As a publicly traded company on the NASDAQ Capital Market, Scilex Holding Company provides investors with liquidity and transparency while subject to regulatory oversight. Investors evaluating Scilex Holding Company should consider industry-specific trends, competitive positioning, and Healthcare sector fundamentals.
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for Scilex Holding Company shareholders
- ⚠Market volatility can significantly impact stock price, especially for smaller companies
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for Scilex Holding Company
- ⚠Investors should consider how Scilex Holding Company fits within their overall portfolio allocation
- ⚠Valuation metrics suggest potential, but require fundamental analysis
Market Cap
175.72M
P/E Ratio
-0.03
Beta
4.62
Investment Analysis & Insights
Key Investment Highlights
- Market Position: Healthcare leader with 175.72M market capitalization
- Trading Volume: 431.01K shares traded today
- Price Range: 52-week range of $3.60 - $34.27
- Exchange: Listed on NASDAQ Capital Market
Financial Metrics
Market Analysis for Scilex Holding Company
Scilex Holding Company (SCLX) operates in the Drug Manufacturers - General industry within the Healthcare sector. With a current market capitalization of 175.72M, the company represents a significant player in its market. The stock is currently trading at $23.22 with a positivedaily change of 22.51%.
The company's 115 employee base and presence on the NASDAQ Capital Marketexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of -0.03, beta of 4.62, and 52-week price range from $3.60 to $34.27when evaluating investment opportunities.
Why Invest in Scilex Holding Company?
Strengths
- • Established market presence in Healthcare
- • Strong financial metrics and market position
- • Listed on major exchange (NASDAQ Capital Market)
- • Experienced leadership under Henry H. Ji
Investment Considerations
- • Monitor sector-specific market trends
- • Track quarterly earnings performance
- • Consider market volatility and beta
- • Evaluate long-term growth potential
Related Healthcare Stocks
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.